Learning how cells fix their broken DNA to understand cancer origins and inform new therapies.
Understanding our immune response to new and evolving viruses to improve treatments for current and emerging threats.
Developing therapies that optimize the cancer-fighting power of immune T cells while reducing side effects.
Studying how a type of bacteria leads to aggressive colorectal cancer to better prevent and treat it.
Improving screening by identifying genetic and other risk factors for prostate cancer in diverse populations.
Learning how immune T cells behave during and after treatment to improve immune-based therapies for children.
Refining blood stem cell transplantation and testing it to treat severe autoimmune diseases.
Researching mosquito- and tick-borne flaviviruses, including dengue and Zika, that threaten people worldwide.
Linking cellular changes to different prostate tumor pathologies to enhance diagnosis.
Illuminating the role of glia, which form one-half of our brain cells, in Alzheimer’s and autism.
Nasa Sinnott-Armstrong, PhD
Distilling complex genetic and environmental factors to better predict disease risk.
Uncovering how blood stem cells repopulate the bone marrow after radiation and transplant.
Improving stem cell transplantation and follow-up to catch relapse early.
Designing new immunotherapies that harness immune T cells to fight lung and skin cancers.
In 2017, we supported Dr. Roland Strong to improve cancer treatment by helping create a tool that identifies “targets” present in cancer cells, but not healthy cells.
Dr. Aude Chapuis, holder of the John C. and Karyl Kay Hughes Endowed Chair, is not building on this work: retraining the body’s own immune cells to recognize targets and attack cancers.
With Obliteride funding, Dr. Jen Adair holder of the Fleischauer Family Endowed Chair in Gene Therapy Translation developed a groundbreaking technology to make gene therapies for cancer more accessible worldwide.
Dr. Hootie Warren continues to help improve treatment around the world, especially in communities with limited access to care.
With early funding from Obliteride, Dr. Johanna Lampe identified nutrients associated with cancer risk, unlocking new insights into diet and risk reduction.
Have fun and help cure cancer faster.